Biomarker ID | 835 |
PMID | 22213075 |
Year | 2011 |
Biomarker | Mutation Status of HSD17B2 |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Tissue |
Subjects | Humans |
Regulation | Allelic Loss in HSD17B2 in Recurrence |
Odds Ratio/Hazard Ratio/Relative Risk | HR = 1.97, (95% CI: 1.06–3.64) |
Effect on Pathways | Pathways Include:- Steroid biosynthesis,Steroid hormone biosynthesis,Oncostatin M, Metabolism |
Experiment | Biochemical Recurrenece (5 years) |
Type of Biomarker | Prognostic |
Cohort | 126 men with intermediate-risk disease were chosen for the study out of which 47 experiened relapse. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.031 |
Method Used | Microarray-based Comparative Genomic Hybridization |
Clinical | No |
Remarks | The results were validated in a surgical cohort of 131 intermediate-risk patients |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | HSD17B2 |